What do our customers say about IntegraGen Genomics?

“The rare disease Foundation is proud to count IntegraGen Genomics as one of it’s partners”

Foundation Maladies Rares “The Foundation for Rare Diseases has partnered with IntegraGen Genomics as part of its call for projects in order to facilitate researchers in the field of rare diseases to have access to the latest high-throughput sequencing technology.”

“The collaboration with IntegraGen has been effective and fruitful. IntegraGen provides the best service to researcher on an ongoing basis and closely interacts with them to identify the best tools adapted to their needs.”

– Celine Hubert , Assistant-Director, Foundation for rare diseases


PhotoSBaulacERIS is in my Favorite tabs, sometimes I log myself on just for a few moments and sometimes, on the contrary, work there several consecutive hours!

“The ERIS computer software developed by IntegraGen Genomics very intuitively and flexibly selects patients. I especially appreciate the quick links the software has with AceView and Alamut , to visualize the literature related to the gene of interest, expression data, online pathogenicity prediction tools “ 

 “I chose to work with IntegraGen Genomics because of their responsiveness and expertise in the field of genomics and the access they provide to new technologies “

– Stéphanie Baulac, Inserm Director , Institute for Brain and Spinal Cord of the ICM


We have set up a genomic platform with IntegraGen dedicated to the sequencing of DNA and RNA in tumor cells

“We could have done it by ourselves but it would have taken at least three years to set up such a facility.”

“With IntegraGen Genomics we were able to get the exome and RNA sequencing done immediately.”

– Professor Eric Solary, Director of Research at Gustave Roussy

.


IntegraGen Genomics is a preferred partner to support us in this technological and scientific revolution

Michael Weber photo“Our team is studying how epigenetic changes in DNA regulate the function of mammalian cells under normal and pathological conditions. The use of high-throughput sequencing for epigenetic mapping helps us understand the epigenetic regulatory pathways in cells and will assist us to identify new therapeutic targets for cancer treatment.”

“We have been working with IntegraGen Genomics since 2012 and they have provided us with technical and scientific expertise along with access to the latest sequencing technologies. We are very satisfied with the timeliness and quality of data they have provided as well as the interactions with the technical experts who have helped us to move forward with new projects.”

– Dr. Michael Weber, Strasbourg School of Biotechnology, Illkirch Graffenstaden France


Pr Hugues de ThéGeCo played an absolutely essential role in the progress of our projects

“We had the opportunity to work with a competent and reactive team who fully understood our questions and quickly responded to our needs with customized solutions. My only regret is not having known about this service sooner.” 

– Prof. Hugues de Thé, Hôpital Saint-Louis, INSERM U944, Paris